SEC Tracker
Get the app

Dermata Therapeutics DRMA

Dermata Therapeutics reports Q3 2026 results

Dermata Therapeutics (DRMA) filed an 8-K with the SEC on Nov 10, 2026, 4:07 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Launched Tome Foundational Treatment on August 25, 2026
  2. Generated first product revenue from direct-to-consumer sales
  3. Completed cosmetic clinical study showing 71% improvement in skin appearance
  4. Initiated clinical trial for second product, Tome Clearing Treatment

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Dermata Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.